International Scientific Publications
© 2007-2026 Science Events Ltd
Termeni de utilizare  ·  Politica de confidențialitate
Language English French Polish Romanian Bulgarian
Conference room
Materials, Methods & Technologies 2026, 28th International Conference
13-16 August, Burgas, Bulgaria
Call for Papers

Materials, Methods & Technologies, Volume 7, 2013

EFFECT OF THE MAIN NON-BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS
Oleg Iaremenko, Ganna Mykytenko, Dmitro Fedkov
Pagini: 421-431
Publicat: 1 Jan 2013
Vizualizări: 249
Descărcări: 22
Rezumat: In this clinical study, the effect of methotrexate (MTX), leflunomide (LF), sulfasalazine (SS) and the combination of disease modifying antirheumatic drugs (DMARDs) on radiological progression in patients with very early, early and advanced rheumatoid arthritis (RA) was determined. It was found that the effectiveness of all variants of DMARD therapy in very early and early RA is equal, while in advanced RA, LF and CBT are significantly superior to MTX and SS. The most important determinants of radiological progression of very early RA are level of antibodies to cyclic citrullinated peptide (anti-CCP) and total radiographic score, early RA - the presence of anti-CCP and total radiographic score, advanced RA - erosion score, level of anti-CCP, elevated levels of CRP and ESR value.
Cuvinte cheie: rheumatoid arthritis, disease duration, disease modifying antirheumatic drugs, radiological progression
Citează acest articol: Oleg Iaremenko, Ganna Mykytenko, Dmitro Fedkov. EFFECT OF THE MAIN NON-BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUGS ON RADIOGRAPHIC PROGRESSION IN PATIENTS WITH DIFFERENT DURATION OF RHEUMATOID ARTHRITIS. Journal of International Scientific Publications: Materials, Methods & Technologies 7, 421-431 (2013). https://www.scientific-publications.net/en/article/1003124/
Înapoi la cuprinsul volumului

Submit Feedback

We value your input! Use this form to report any concerns or provide feedback on our published articles. All submissions will be kept confidential.

Prin utilizarea acestui site, sunteți de acord cu Politica noastră de confidențialitate și Termenii și condițiile de utilizare. Folosim cookie-uri, inclusiv pentru analiză, personalizare și reclame.